More on OraSure Technologies (OSUR): Q4 beats on both EPS and revenue estimates, but the stock is trading lower in the post-session due to weak guidance. Total sales declined 7% Y/Y, as higher cryosurgical systems sales were offset by lower sales of it's infectious disease testing, substance abuse testing and insurance risk assessment products. For FY13, the company expects a Q1 EPS loss of $0.19 - $0.18 per share on revenues of $20M - $21M. The Street view is for a loss of $0.12 per share on revenues of $23.08M. Shares -4% AH.